CN101646944A - 检测人免疫缺陷病毒的方法 - Google Patents

检测人免疫缺陷病毒的方法 Download PDF

Info

Publication number
CN101646944A
CN101646944A CN200880002505A CN200880002505A CN101646944A CN 101646944 A CN101646944 A CN 101646944A CN 200880002505 A CN200880002505 A CN 200880002505A CN 200880002505 A CN200880002505 A CN 200880002505A CN 101646944 A CN101646944 A CN 101646944A
Authority
CN
China
Prior art keywords
seq
bioengineered
antigen
binding
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880002505A
Other languages
English (en)
Chinese (zh)
Inventor
卡尔·萨克西拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Next Biomed Technologies NBT Oy
Original Assignee
Next Biomed Technologies NBT Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Technologies NBT Oy filed Critical Next Biomed Technologies NBT Oy
Publication of CN101646944A publication Critical patent/CN101646944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880002505A 2007-01-17 2008-01-17 检测人免疫缺陷病毒的方法 Pending CN101646944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20075028A FI120376B (fi) 2007-01-17 2007-01-17 Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI20075028 2007-01-17
US60/885,352 2007-01-17

Publications (1)

Publication Number Publication Date
CN101646944A true CN101646944A (zh) 2010-02-10

Family

ID=37745720

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880002505A Pending CN101646944A (zh) 2007-01-17 2008-01-17 检测人免疫缺陷病毒的方法

Country Status (8)

Country Link
US (1) US20100048407A1 (enExample)
EP (1) EP2109772A4 (enExample)
JP (1) JP2010516660A (enExample)
CN (1) CN101646944A (enExample)
AU (1) AU2008206881A1 (enExample)
CA (1) CA2675122A1 (enExample)
FI (1) FI120376B (enExample)
WO (1) WO2008087254A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
US6818392B2 (en) * 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers

Also Published As

Publication number Publication date
EP2109772A4 (en) 2010-09-29
WO2008087254A8 (en) 2009-07-30
AU2008206881A1 (en) 2008-07-24
CA2675122A1 (en) 2008-07-24
FI20075028A0 (fi) 2007-01-17
FI20075028L (fi) 2008-07-18
US20100048407A1 (en) 2010-02-25
WO2008087254A2 (en) 2008-07-24
JP2010516660A (ja) 2010-05-20
EP2109772A1 (en) 2009-10-21
FI120376B (fi) 2009-09-30

Similar Documents

Publication Publication Date Title
ES2295292T3 (es) Anticuerpo monoclonal anti-nucleo de vhc.
CN104520318B (zh) 针对jc病毒的vp1蛋白的人单克隆抗体
Van Binsbergen et al. Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 Ag detection: a new generation Vironostika HIV Uni-Form II
Khamassi et al. The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals
Friedrich et al. Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization
Opalka et al. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay
CN106939034B (zh) 用于鉴定受试者所感染的hev基因型的方法和试剂盒
De Leon et al. B cell epitope mapping: The journey to better vaccines and therapeutic antibodies
CN101646944A (zh) 检测人免疫缺陷病毒的方法
US8735328B2 (en) Fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins
JP7595249B2 (ja) 抗ＨＩＶ－１ Ｖ３抗体１Ｃ１０（０．５γ）に結合する抗体及びその抗原結合断片並びにその応用
Liu et al. Bispecific monoclonal antibodies against a viral and an enzyme: utilities in ultrasensitive virus ELISA and phage display technology
Jackson et al. Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions.
Kantrong et al. A single amino acid substitution at N-terminal region of coat protein of turnip mosaic virus alters antigenicity and aphid transmissibility
Zhang et al. Mimotopes selected by biopanning with high-titer HIV-neutralizing antibodies in plasma from Chinese slow progressors
JP4892548B2 (ja) Ｈｉｖに対して中和活性を有する抗体又はその断片
JP4476327B2 (ja) 修飾ｈｉｖ−１ペプチドおよび抗ｈｉｖ抗体の検出におけるその使用
EP4194054A1 (en) Camelid antibodies for use in therapy and diagnosis
Burciaga-Flores et al. A New Approach in DENV Diagnostic based on Linear Peptides Obtained by Phage Display
CN114437205A (zh) 抗冠状病毒抗体及其应用
JP2000157268A (ja) Ｈｉｖ―１ｏ群の検出用のペプチド
Wang MD, Shanxi Medical University, 1998 M. Sc., The Fourth Military Medical University, 2001
Wang Specificity and polyreactivity of the antibody response during natural HIV-1 infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100210